CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities
Rita Raddatz, Michael Williams(Hospital of the University of Pennsylvania), John A. Gruner, Edward R. Bacon, Maciej Gąsior(National Institute of Neurological Disorders and Stroke), Dorothy G. Flood(Brandywine Photonics (United States)), Donna Bozyczko‐Coyne, John P. Mallamo, Hervé Schaffhauser, Robert L. Hudkins(State Street (United States)), Mark A. Ator, Lisa D. Aimone, Michael J. Marino, Siyuan Le, Joanne R. Mathiasen, Emir Duzic
Cited by 58
Related Papers
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
The Neuropharmacology of the Ketogenic Diet
|Pediatric Neurology|2007|320
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
|Expert Opinion on Drug Discovery|2016|113